About this trial
Everybody's skin has bacteria that normally lives on it. Previous research has shown that people with eczema (or atopic dermatitis \[AD\]) have much higher concentrations of a certain bacteria (S. aureus), especially when their disease is active but little is known about the role that this bacteria plays in psoriasis (i.e. disease severity, biomarkers and skin barrier function). The overarching purpose of this longitudinal study is to understand how the abundance of skin S. aureus (and several commensal bacteria) change as a consequence of standard of care treatment in the URMC dermatology clinics. Other assays and biospecimens will also be collected to address a number of questions.
Eligibility criteria
Qualifiers
≥13 to 65 years of age (inclusive) for PS, ≥13 for AD and NA, male or female
Optional Bx sub study - only adults (18-65 yrs; inclusive only)
Able to understand protocol and give consent
Able to keep clinic/study appointments and comply with study related procedures
Disqualifiers
Unwilling and/or unable to complete informed consent process
<13 or > 65 years of age for PS, >13 for AD and NA
AD subjects: disease without upper extremity, lower extremity, or trunk lesions
AD subjects: total disease severity less than moderate (EASI <12), depending on enrollment
Trial design
Treatments tested in this trial
- AD subject visit sampling procedures
- PS subject visit sampling procedures
- Healthy control visit sampling procedures